PDS Biotechnology Corporation
PDSB
$1.10
-$0.20-15.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -19.84% | 5.60% | -17.95% | -3.50% | -3.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.32% | -20.03% | -12.22% | -9.82% | -29.27% |
| Operating Income | 9.32% | 20.03% | 12.22% | 9.82% | 29.27% |
| Income Before Tax | 4.90% | 16.01% | -2.58% | 8.91% | 27.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 4.90% | 16.01% | -13.28% | 19.94% | 27.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.90% | 16.01% | -13.28% | 19.94% | 27.03% |
| EBIT | 9.32% | 20.03% | 12.22% | 9.82% | 29.27% |
| EBITDA | 9.34% | 20.06% | 12.24% | 9.84% | 29.32% |
| EPS Basic | 30.88% | 34.04% | 9.47% | 31.22% | 38.38% |
| Normalized Basic EPS | 30.92% | 34.05% | 18.00% | 21.70% | 38.35% |
| EPS Diluted | 30.88% | 34.04% | 9.47% | 31.22% | 38.38% |
| Normalized Diluted EPS | 30.92% | 34.05% | 18.00% | 21.70% | 38.35% |
| Average Basic Shares Outstanding | 37.62% | 27.34% | 25.10% | 16.39% | 18.40% |
| Average Diluted Shares Outstanding | 37.62% | 27.34% | 25.10% | 16.39% | 18.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |